James Shannon Biography and Net Worth

James Shannon, M.D., has served as a member of our board of directors since June 2024 and brings more than 30 years of drug development and leadership experience to Xilio. From 2012 until his retirement in 2015, Dr. Shannon served as the chief medical officer of GlaxoSmithKline PLC. Prior to that, Dr. Shannon spent more than a decade with Novartis, including as global head of pharma development, where he was responsible for all of Novartis’ development activities, from preclinical through Phase 4 clinical development, and oversaw an annual development budget of approximately $4 billion. Dr. Shannon currently serves as chair of the board of directors of MannKind Corporation and ProQR Therapeutics N.V. Dr. Shannon also serves on the boards of directors of Leyden Laboratories B.V., a private biotechnology company, and MyTomorrows, a private health technology company. Dr. Shannon is trained in Medicine and Cardiology and received his undergraduate degree and M.D. from Queen’s University in Belfast, Northern Ireland. Dr. Shannon is also a Member of the Royal College of Physicians (UK).